Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Comparative Rx Economic Claims Without Head-to-Head Trials Risky – J&J’s Jimenez

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson Associate General Counsel Freddy Jimenez acknowledges a continued reluctance among biopharmaceutical companies to make health care economic claims in the absence of further guidance from FDA.


Related Content

FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
FDA Guidance On Health Care Economic Data Is Coming In 2015
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts